Why the study?
Does tanshinone IIA inhibit apolipoprotein B-100 and triglyceride secretion in human HepG2 cells?
Does tanshinone IIA inhibit apolipoprotein B-100 and triglyceride secretion in human HepG2 cells?
Tanshinone IIA inhibits apolipoprotein B-100 and triglyceride secretion in human liver cells, highlighting a potential mechanism for its cardiovascular benefits.
Hypothesis-generating for tanshinone IIA in dyslipidemia; should not change practice without human trials.
Salvia miltiorrhiza Bunge is known to be effective for the treatment of cardiovascular diseases. Here, we have isolated tanshinone IIA (T-IIA) from S. miltiorrhiza Bunge. The aim of this study is to address the mechanisms where apolipoprotein B-100 (ApoB) regulation is associated with T-IIA, since T-IIA regulates the lipoprotein metabolism in liver cells. Human HepG2 cells treated with T-IIA for 24 h exerted a dose-dependent inhibitory effect on ApoB secretion together with triglyceride. However, another secretory protein, albumin, was unaffected by T-IIA treatment, indicating that the effect of T-IIA is specific for ApoB secretion. T-IIA decreased the transcription level of microsomal triglyceride transfer protein gene, suggesting that lipoprotein assembly is likely to be involved in the inhibited ApoB secretion. Interestingly, T-IIA inhibited ApoB secretion via a proteasome-dependent pathway. Our results suggest that T-IIA is an influential inhibitor of ApoB secretion and triglyceride secretion in liver cells.
No takes yet. Share an insight, caveat, or question.
Kang et al. (2008) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: